Efficacy and effectiveness of influenza vaccine and pneumococcal conjugated vaccine - 13 (PCV13) in patients with chronic kidney disease

Efficacy and effectiveness of influenza vaccine and pneumococcal conjugated vaccine â€“ 13 (PCV13) in patients with chronic kidney disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20160609002

Enrollment

1584

Registered

2016-06-09

Start date

2016-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease Influenza vaccine 13&#45

Interventions

not get PCV13 and not complete flu vaccine,get both flu vaccine 3 years consecutively and PCV13,get PCV13 and not complete flu vaccine,get flu vaccine 3 years consecutively and not get PCV13

Prevention,Prevention,Prevention,Prevention

control,FluPCV,PCV,Flu

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Chronic kidney disease stage 3 - 5

Exclusion criteria

Exclusion criteria: 1. Allergic to influenza vaccine and/or PCV13

Design outcomes

Primary

Measure	Time frame
communityâ€”acquired pneumonia from any cause 3 years vaccine efficacy	—

Secondary

Measure	Time frame
hospitalization from pneumonia from any cause 3 years vaccine efficacy,respiratory failure from respiratory tract infection from any cause 3 years vaccine efficacy,ICU admission from respiratory tract infection from any cause 3 years vaccine efficacy,mortality from any cause 3 years vaccine efficacy,enzyme-linked immunospot (ELISPOT) assay for influenza immune response 3 years vaccine efficacy,incidence of pneumococcal pneumonia 3 years vaccine efficacy,incidence of invasive pneumococcal disease 3 years vaccine efficacy,mortality from invasive pneumococcal disease 3 years vaccine efficacy	—

Measure

Time frame

hospitalization from pneumonia from any cause 3 years vaccine efficacy,respiratory failure from respiratory tract infection from any cause 3 years vaccine efficacy,ICU admission from respiratory tract infection from any cause 3 years vaccine efficacy,mortality from any cause 3 years vaccine efficacy,enzyme-linked immunospot (ELISPOT) assay for influenza immune response 3 years vaccine efficacy,incidence of pneumococcal pneumonia 3 years vaccine efficacy,incidence of invasive pneumococcal disease 3 years vaccine efficacy,mortality from invasive pneumococcal disease 3 years vaccine efficacy

—

Countries

Thailand

Contacts

Public ContactRatima Samorn

Queensaovabha Memorial Institute

ratima.s@redcross.or.th02-2520161

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Efficacy and effectiveness of influenza vaccine and pneumococcal conjugated vaccine &#45; 13 (PCV13) in patients with chronic kidney disease